Effect of Omalizumab for Autoimmune Progesterone Dermatitis Refractory

Total Page:16

File Type:pdf, Size:1020Kb

Effect of Omalizumab for Autoimmune Progesterone Dermatitis Refractory Varghese et al. Allergy Asthma Clin Immunol (2021) 17:58 Allergy, Asthma & Clinical Immunology https://doi.org/10.1186/s13223-021-00561-2 CASE REPORT Open Access Efect of omalizumab for autoimmune progesterone dermatitis refractory to bilateral oophorectomy: a case report Akshay Varghese1* , Terri Paul2, Harold Kim3, Stan Van Uum2, Peter Vadas4 and Alescia Azzola1 Abstract Background: Autoimmune progesterone dermatitis (APD) is a rare skin condition caused by sensitivity to high levels of progesterone secreted during the luteal phase of the menstrual cycle. This may be due to various pathophysiological mechanisms including a Type I and Type IV hypersensitivity reaction. Here we present the case of a patient with APD whose episodic fares were controlled by the addition of omalizumab, after a bilateral oophorectomy failed to resolve her symptoms. Case Presentation: A 34-year-old female presented to our Endocrine clinic with marked Cushingoid features secondary to high-dose oral prednisone prescribed for APD diagnosed 6 years earlier. She frst developed a pruritic maculopapular rash on her arms and legs just after the birth of her second child in 2009. The rash was also associated with headaches and difuse angioedema. Symptoms occurred for 1–2 weeks, in a cyclical fashion, during the luteal phase of each menstrual cycle and subsided within a few days after menses. The severity of symptoms increased as time went on, and fare-ups began to also include dyspnea, nausea, vomiting and abdominal pain. Her symptoms improved with administration of oral prednisone, but she continued to experience breakthrough symptoms. After multiple failed treatment modalities, she elected bilateral oophorectomy in 2018. However, her symptoms of APD persisted and she still required high-dose oral prednisone. Her condition was further complicated by vasomotor menopausal symptoms and progressive iatrogenic Cushing’s syndrome. She eventually was started on Omalizumab, which suppressed further recurrences of APD symptoms and allowed her to wean of prednisone. Vasomotor menopausal symptoms responded well to the addition of conjugated estrogens with bazedoxifene. However, her symptoms of difuse bony pain and arthralgias which started whilst on prednisone have persisted in spite of discontinuing prednisone. Conclusions: To our knowledge, this is only the third case of APD which was successfully treated with Omalizumab and the frst case where a bilateral oophorectomy failed to resolve symptoms of APD in the literature. This case also demonstrates the complications of vasomotor menopausal symptoms secondary to a bilateral oophorectomy, as well as the adverse efects of long-term glucocorticoid therapy. Keywords: Autoimmune progesterone dermatitis, Bilateral oophorectomy, Omalizumab Background Autoimmune progesterone dermatitis (APD) is a rare condition, with a literature review from 2016 *Correspondence: [email protected] 1 Division of Internal Medicine, Northern Ontario School of Medicine, documenting approximately 90 cases [1]. Patients with Sudbury, ON, Canada APD are sensitive to the high levels of progesterone Full list of author information is available at the end of the article secreted during the luteal phase of the menstrual cycle © The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Varghese et al. Allergy Asthma Clin Immunol (2021) 17:58 Page 2 of 5 [2]. Depending on whether the reaction is IgE-mediated, or T-cell mediated, APD can present in various forms, such as eczema, folliculitis, and erythema multiforme, but can also progress to more acutely severe manifestations such as dyspnea and anaphylaxis [2]. Symptom onset is typically 1 week prior to menses and symptoms resolve a few days after the onset of menstruation [3, 4]. Although the pathogenesis of the disease is not yet fully understood, it has been postulated to involve Type I and Type IV hypersensitivity reactions [4]. Progesterone has been noted to stimulate immunoglobulin E (IgE)- mediated mast cell degranulation [2, 5]. Additionally, progesterone sensitivity may be also due to cell-mediated Fig. 1 Acute angioedema—patient photograph, consent obtained immunity, due to prior uptake of progesterone by antigen-presenting cells and stimulation of T-helper cells [4]. Furthermore, cross-reactivity with other endogenous steroid hormones such as 17-α-hydroxy-progesterone abdominal cramping. All symptoms continued to follow may also be a plausible mechanism for increased the identical luteal phase cyclical onset of presentation. progesterone sensitivity in APD patients [1]. For several years, she was treated with numerous Te diagnosis of APD is based on the unique cyclical medications, including frst and second generation H1 appearance of symptoms during a menstrual cycle. If and H2 histamine antagonists, tricyclic antidepressants, APD is IgE-mediated, the diagnosis is confrmed by calcineurin inhibitor immunosuppressant therapy a positive wheal and fare response to skin testing with and psoralen and ultraviolet A (PUVA) therapy. progesterone [6]. Various treatment options have been Tese treatments were all unsuccessful in improving described for APD, including gonadotrophin-releasing her symptoms. She was eventually started on oral hormone (GnRH) agonists (suppressing progesterone prednisone in doses of up to 100 mg daily. Symptomatic production), oral contraceptives, tamoxifen, improvement was achieved with corticosteroid use, antihistamines, prednisone, dapsone, thalidomide, but pre-menstrual fare-ups would still occur quite azathioprine and danazol [7–9]. However, if these often. After three years of persistent symptoms, she was therapies fail, or cause intolerable side efects, a bilateral referred to an Immunologist who established a likely oophorectomy can be performed as a more durable diagnosis of autoimmune progesterone dermatitis with solution [7]. potential catamenial anaphylaxis. Tis was confrmed using a progesterone skin test. Her serum tryptase at baseline was low at 2.8 Ug/L (3.8–11.4 Ug/L). Case Presentation She was then started on a trial of a low-dose oral contraceptive pill, which contained 0.02 mg ethinyl A 34-year-old female with pronounced Cushingoid estradiol and 0.1 mg of levonorgestrel, in an attempt to features presented to our Endocrinology clinic in 2018. be desensitized to progesterone. High dose prednisone She had been taking high dose oral prednisone for a was prescribed for fare-ups. Tis was an attempt to diagnosis of severe autoimmune progesterone urticaria, wean her of prednisone. After 6 months, there was still refractory to bilateral oophorectomy. no improvement in her symptoms. Te reintroduction A raised pruritic macular erythematous rash initially of antihistamine therapy, intensifed up to quadruple appeared on her arms and legs in 2009, two to three therapy, as well as a trial of cyclosporine therapy also did days after the birth of her second child. Tis rash was not allow for adequate prednisone taper. Gonadotropin- associated with headaches, and difuse angioedema of releasing hormone (GnRH) therapy was also her hands, feet, lips, and eyelids (Fig. 1). Te pruritic rash recommended. However, the patient declined additional continued to occur in a cyclical fashion, appearing one medical therapies. Due to the long-term use of high-dose to two weeks prior to each menses and resolving within prednisone, she developed Cushingoid features including a few days of menstruation onset. Six months after the moon face, violaceous striations, alopecia, and central post-partum period, in tandem with the return of her adiposity Fig. 2—left panel). menstrual cycles, her symptoms quickly progressed from ( Due to the progressive side efects of prednisone as well cyclic urticaria to systemic symptoms such as dyspnea. as persistent symptoms, she elected to undergo a bilateral Her fare-ups also coincided with nausea, dizziness, and oophorectomy at age 34 in June 2018. Tere was short Varghese et al. Allergy Asthma Clin Immunol (2021) 17:58 Page 3 of 5 post-oophorectomy. To our knowledge, this is the frst case where a bilateral oophorectomy procedure may have failed to resolve symptoms of APD. However, one potential publication bias could indeed be a lack of reporting of non-responsive cases. Tree months following bilateral oophorectomy, she presented to our Endocrine clinic for an initial consultation for Cushing syndrome while being treated with 50 mg of daily prednisone. In search of a prednisone sparing treatment for her APD, we initiated Omalizumab (Xolair) monoclonal
Recommended publications
  • PATIENT FACT SHEET (Deltasone)
    Prednisone PATIENT FACT SHEET (Deltasone) Prednisone (Deltasone) is part of a potent class of inflammatory conditions, including redness, anti-inflammatory agents, known as corticosteroids, swelling and pain. Prednisone is used to treat which are used to control inflammation of the rheumatoid arthritis, lupus, vasculitis, and many joints and organs. It is often used to treat a variety of other inflammatory diseases. WHAT IS IT? Dosing of prednisone varies widely depending on tablets take effect about 6 hours after taking the the state of the disease being treated. Doses used dose. Prednisone stops working soon after stopping in rheumatoid arthritis are commonly 5-10mg daily, the medication. If you have been taking prednisone while doses needed in lupus and vasculitis are often regularly for longer than 2 weeks, do not stop it 80mg daily, or sometimes higher. Prednisone usually suddenly. Instead, you should discuss a tapering HOW TO achieves its effect within 1-2 hours. The delayed release schedule with your physician. TAKE IT Most side effects are related to the dose administered medications, there is an increased risk of infection when and duration of treatment, so the goal is to use it at combining prednisone with other medications that the lowest effective dose for the shortest period of time affect your immune system. Additionally, when taking necessary. Some potential side effects include easy prednisone with NSAIDs (such as naproxen or ibuprofen), bruising, osteoporosis (or weakened bones), diabetes, there can be an increased risk of stomach ulcers. Make hypertension, weight gain, cataracts, glaucoma, and sure to review all of your medications with your physician SIDE a bone disorder called avascular necrosis.
    [Show full text]
  • Celestone Syrup Page 1 Nda 14-215/S-009, 015
    CELESTONE SYRUP PAGE 1 NDA 14-215/S-009, 015 CELESTONE® betamethasone syrup, USP DESCRIPTION CELESTONE Syrup, for oral administration, contains 0.6 mg betamethasone in each 5 mL. The inactive ingredients for CELESTONE Syrup include: alcohol (less than 1%), citric acid, FD&C Red No. 40, FD&C Yellow No. 6, flavors, propylene glycol, sodium benzoate, sodium chloride, sorbitol, sugar, and water. The formula for betamethasone is C22H29F05 and it has a molecular weight of 392.47. Chemically, it is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione and has the following structure: (Add structure) Betamethasone is a white to practically white, odorless crystalline powder. It melts at about 240°C with some decomposition. Betamethasone is sparingly soluble in acetone, alcohol, dioxane, and methanol; very slightly soluble in chloroform and ether; and is insoluble in water. CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt- retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, such as betamethasone, are primarily used for their anti-inflammatory effects in disorders of many organ systems. A derivative of prednisolone, betamethasone has a 16β­ methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium- and water-retaining properties of the fluorine atom bound at carbon 9. INDICATIONS AND USAGE Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Differential Effects of Hydrocortisone, Prednisone, And
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Nebesio et al. International Journal of Pediatric Endocrinology (2016) 2016:17 DOI 10.1186/s13633-016-0035-5 RESEARCH Open Access Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia Todd D. Nebesio1*, Jamie L. Renbarger2,3, Zeina M. Nabhan1, Sydney E. Ross2, James E. Slaven4, Lang Li5, Emily C. Walvoord1 and Erica A. Eugster1 Abstract Background: Little is known about the comparative effects of different glucocorticoids on the adrenal and growth hormone (GH) axes in children with congenital adrenal hyperplasia (CAH). We sought to compare the effects of hydrocortisone (HC), prednisone (PDN), and dexamethasone (DEX) in children with classic CAH and to investigate a potential role of pharmacogenetics. Methods: Subjects were randomly assigned to three sequential 6-week courses of HC, PDN, and DEX, each followed by evaluation of adrenal hormones, IGF-1, GH, and body mass index (BMI). Single nucleotide polymorphism (SNP) analysis of genes in the glucocorticoid pathway was also performed. Results: Nine prepubertal subjects aged 8.1 ± 2.3 years completed the study. Mean ACTH, androstenedione, and 17-hydroxyprogesterone (17-OHP) values were lower following the DEX arm of the study than after subjects received HC (p ≤ 0.016) or PDN (p ≤ 0.002). 17-OHP was also lower after HC than PDN (p < 0.001). There was no difference in IGF-1, GH, or change in BMI. SNP analysis revealed significant associations between hormone concentrations, pharmacokinetic parameters, and variants in several glucocorticoid pathway genes (ABCB1, NR3C1, IP013, GLCCI1).
    [Show full text]
  • Inhaled Budesonide and Prednisone Led to Similar Rates of Asthma Relapse After Emergency Department Discharge
    Evid Based Med: first published as 10.1136/ebm.5.5.139 on 1 September 2000. Downloaded from Inhaled budesonide and prednisone led to similar rates of asthma relapse after emergency department discharge FitzGerald JM, Shragge D, Haddon J, et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J 2000 Jan/Feb;7:61–7. QUESTION: In patients who are discharged from the emergency department after a severe acute asthma attack, do high doses of prednisone and inhaled budesonide lead to similar rates of asthma relapse? Design Inhaled budesonide v prednisone in patients discharged from the emergency department after ‡ Randomised (unclear allocation concealment*), blinded a severe acute exacerbation of asthma {clinicians, patients, outcome assessors, and statisti- Outcomes at cians}†,* controlled trial with 7–10 day follow up. 7 to 10 days Budesonide Prednisone RRR (95% CI) NNT (CI) Setting Relapse rate 10% 12% 15% (−94 to 63) Not significant 3 university affiliated urban emergency departments in ‡Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. Canada. Patients 185 patients who were 15–70 years of age, had an acute asthma exacerbation, were well enough to be discharged (postbronchodilator FEV1 > 50% of predicted normal rate), and were able to use Turbuhaler correctly. Exclusion criteria included chronic obstructive pulmonary disease, intolerance to systemic glucocorticosteroids, peptic ulcer COMMENTARY disease, active tuberculosis, fungal infection, type 1 diabetes mellitus, moderate to severe hypertension, preg- A particular strength of the study by FitzGerald et al is that it nancy, lactation, or no effective contraception use (for had sufficient power to assess whether the 2 interventions women of childbearing age).
    [Show full text]
  • Inhaled and Oral Corticosteroids
    Inhaled and Oral Corticosteroids Corticosteroids (steroids) are medicines that are used to treat many chronic diseases. Corticosteroids are very good at reducing inflammation (swelling) and mucus production in the airways of the lungs. They also help other quick-relief medicines work better. The steroids (corticosteroids) used to treat asthma and other chronic lung diseases are not the same as anabolic steroids, used illegally by some athletes for bodybuilding. Corticosteroids do not affect the liver or cause sterility. Does the Body Make Steroids? Corticosteroids are similar to cortisol, a hormone produced by the adrenal glands in the body. Cortisol is one of the body's own natural steroids. Cortisol is essential for life and well being. During stress, our bodies produce extra cortisol to keep us from becoming very sick. Normally the adrenal glands release cortisol into the blood stream every morning. The brain monitors this amount and regulates the adrenal function. It cannot tell the difference between its own natural cortisone and that of steroid medicines. Therefore, when a person takes high doses of steroids over a long time, the brain may decrease or stop cortisol production. This is called adrenal supression. Health care providers generally decrease a steroid dosage slowly to allow the adrenal gland to recover and produce cortisol at a normal level again. If you have been on steroids long- term do not stop taking them suddenly. Follow your doctor’s prescription. What are Some Steroid Medicines? Steroid medicines are available as nasal sprays, metered- dose-inhalers (inhaled steroids), oral forms (pills or syrups), injections into the muscle (shots) and intravenous (IV) solutions.
    [Show full text]
  • Pharmacologic Characteristics of Corticosteroids 대한신경집중치료학회
    REVIEW J Neurocrit Care 2017;10(2):53-59 https://doi.org/10.18700/jnc.170035 eISSN 2508-1349 Pharmacologic Characteristics of Corticosteroids 대한신경집중치료학회 Sophie Samuel, PharmD1, Thuy Nguyen, PharmD1, H. Alex Choi, MD2 1Department of Pharmacy, Memorial Hermann Texas Medical Center, Houston, TX; 2Department of Neurosurgery and Neurology, The University of Texas Medical School at Houston, Houston, TX, USA Corticosteroids (CSs) are used frequently in the neurocritical care unit mainly for their anti- Received December 7, 2017 inflammatory and immunosuppressive effects. Despite their broad use, limited evidence Revised December 7, 2017 exists for their efficacy in diseases confronted in the neurocritical care setting. There are Accepted December 17, 2017 considerable safety concerns associated with administering these drugs and should be limited Corresponding Author: to specific conditions in which their benefits outweigh the risks. The application of CSs in H. Alex Choi, MD neurologic diseases, range from traumatic head and spinal cord injuries to central nervous Department of Pharmacy, Memorial system infections. Based on animal studies, it is speculated that the benefit of CSs therapy Hermann Texas Medical Center, 6411 in brain and spinal cord, include neuroprotection from free radicals, specifically when given Fannin Street, Houston, TX 77030, at a higher supraphysiologic doses. Regardless of these advantages and promising results in USA animal studies, clinical trials have failed to show a significant benefit of CSs administration Tel: +1-713-500-6128 on neurologic outcomes or mortality in patients with head and acute spinal injuries. This Fax: +1-713-500-0665 article reviews various chemical structures between natural and synthetic steroids, discuss its E-mail: [email protected] pharmacokinetic and pharmacodynamic profiles, and describe their use in clinical practice.
    [Show full text]
  • Prednisolone & Prednisone
    PATIENT INFORMATION ON PREDNISOLONE & PREDNISONE (Also known as corticosteroids / cortisone / steroids) (Examples of brand names: Panafcort, Panafcortelone, Predsone, Predsolone, Solone, Sone) This information sheet has been produced by What is prednisolone? the Australian Rheumatology Association to help you understand the medicine that has been Corticosteroids are hormones that are produced prescribed for you. It includes important naturally in the body. They are necessary for information about: normal working of the body. ñ how you should take your medicine Prednisolone and prednisone are man-made ñ what are the possible side effects corticosteroids (also called steroids for short). ñ what tests you should have to monitor your Man-made corticosteroids are used to treat condition and to detect unwanted effects inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus ñ other precautions you should take when you are taking prednisolone or prednisone. (SLE/lupus) and other inflammatory disease. They have a strong anti-inflammatory effect and Please read it carefully and discuss it with your reduce the swelling and pain in joints and other doctor. organs. They do not cure the disease. They should not be confused with male or Important things to remember: female steroid hormones, which are known for their misuse among athletes. ñ While taking prednisolone you should see your treating doctor regularly to make Prednisolone is the most common type of sure the treatment is working as it should corticosteroid prescribed. Although prednisone and to minimise any possible side effects. is slightly different the information contained in this document also applies to that medication. ñ You should not stop your treatment unless your doctor tells you to.
    [Show full text]
  • Progestagens and Corticosteroids in the Management of Cancer Cachexia
    Chapter 10.11 Progestagens and Corticosteroids in the Management of Cancer Cachexia Davide Tassinari, Marco Maltoni Introduction rect clinical research can be hard in palliative care, because of the peculiar characteristics of patients Over the past few years, many authors have with advanced or terminal disease. The treatment approached the problem of the treatment of can- of cancer cachexia with corticosteroids or prog- cer cachexia focusing on either the knowledge of estagens is based on a quite solid evidence of the main pathogenetic events, or the outcomes of activity. However, despite the large number of tri- the treatment in terms of symptoms or improve- als supporting their use in clinical practice, some ment in quality of life [1–8]. The relevance of clini- aspects still remain undefined and deserve to be cal investigations of cancer anorexia-cachexia has looked at in more depth. epidemiological and clinical roots, considering that it is very frequent in advanced and terminal disease (up to 40% of patients with advanced dis- Biological Rationale of Medical Treatment of ease, and more than 80% of terminal patients), and Cancer Cachexia that its clinical manifestations often represent a source of great concern for both patients and rela- Recently, many authors have investigated the dif- tives [1–5]. The clinical approach to cancer ferent pathogenetic events responsible for the clin- anorexia-cachexia has been directed towards dif- ical behaviour of cancer cachexia, and suggested a ferent targets, and it can be aetiological, patho- role for both tumour cells and immuno-mediated genetic or symptomatic according to the attention responses to tumour growth, as important events paid to tumour growth, the main pathogenetic in the pathogenesis of the syndrome [1, 7, 9–41].
    [Show full text]
  • Conversion of Cortisone to Cortisol and Prednisone to Prednisolone
    22 April 1967 Histocompatibility Tests-Johnson and Russell MEBRITJSH 205 Bach, F., and Hirschhorn, K. (1964). Science, 143, 813. Harris, R., Clarke, C. A., Jones, A. L., Sheppard, P. M., Lehane, D., Bain, B., and Lowenstein, L. (1964). Ibid., 145, 1315. McCarthy, M., Lawler, S. D., and Shatwell, H. S. (1966). Brit. Vas, M. R., and Lowenstein, L. (1964). Blood, 23, 108. med. 7., 1, 509. Brent, L., and Medawar, P. B. (1963). Brit. med. 7., 2, 269. Hirschhorn, K. (1965). In Histocompatibility Testing, edited by P. S. - (1964). Nature (Lond.), 204, 90. Russell and H. J. Winn, Publication No. 1229, Nat. Acad. Sci., Bridges, J. M., Nelson, S. D., and McGeown, M. G. (1964). Lancet, 1, Washington, p. 177. 581. Huggins, C. E. (1964). Ann. Surg., 160, 643. Chen, P. S. (1958). Proc. Soc. exp. Biol. (N.Y.), 98, 546. Johnson, G. J., and Russell, P. S. (1965). Nature (Lond.), 208, 343. Gray, J. G., and Russell, P. S. (1963). Lancet, 2, 863. Moorhead, J. F., and Patel, A. R. (1964). Brit. med. 7., 2, 1111. - (1965). In Histocompatibility Testing, edited by P. S. Russell Russell, P. S. (1966). In Histocompatibility Testing 1965, edited by HE and H. J. Winn. Publication No. 1229, Nat. Acad. Sci., Washington, Balner, F. J. Cleton, and J. G. Eernissc, p. 233. Copenhagen. p. 105. Streilein, J. W. (1966). Ibid., p. 241. Conversion of Cortisone to Cortisol and Prednisone to Prednisolone J. S. JENKINS,* M.D., M.R.C.P.; P. A. SAMPSON,t M.B., CH.B. Brit. med. J., 1967, 2, 205-207 Though cortisone has been widely used since Hench et al.
    [Show full text]
  • Dexamethasone Compared to Prednisone for the Treatment of Children with Acute Asthma Exacerbations
    CME REVIEW ARTICLE Dexamethasone Compared to Prednisone for the Treatment of Children With Acute Asthma Exacerbations Ruth Abaya, MD, MPH,* Laura Jones, PharmD,† and Joseph J. Zorc, MD, MSCE‡ • Apply available evidence on corticosteroid treatment for acute Abstract: Systemic corticosteroids are recommended in clinical practice asthma to design an appropriate emergency department treat- guidelines for the treatment of acute asthma exacerbation based on evi- ment protocol. dence demonstrating reduced hospitalizations and improved outcomes af- ter administration in the emergency department. Although prednisone and related oral preparations have been recommended previously, re- OVERVIEW searchers have assessed dexamethasone as an alternative based on its lon- Effective treatment with corticosteroids is a key component ger biologic half-life and improved palatability. Systematic reviews of of high-quality care for children presenting to the emergency de- multiple small trials and 2 larger trials have found no difference in revisits partment (ED) for acute asthma exacerbation. Asthma is a leading to the emergency department compared to prednisone for dexamethasone cause of pediatric hospitalization, and systematic reviews of clin- given either as an intramuscular injection or orally. Studies of oral admin- ical trials have demonstrated a clear effect of corticosteroids on istration have found reduced emesis for dexamethasone compared to pred- reducing admission and other measures of acute severity.1 The nisone both in the emergency department
    [Show full text]
  • A Randomized, Placebo-Controlled Trial of Oral Beclomethasone Dipropionate As a Prednisone-Sparing Therapy for Gastrointestinal Graft-Versus-Host Disease
    TRANSPLANTATION A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease David M. Hockenbery,1 Scott Cruickshank,2 Timothy C. Rodell,2 Ted Gooley,1 Friedrich Schuening,3 Scott Rowley,4 Donald David,5 Mark Brunvand,6 Brian Berryman,7 Sunil Abhyankar,8 Michelle Bouvier,1 and George B. McDonald,1 for the orBec GVHD Study Group 1Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle; 2DOR BioPharma Inc, Miami, FL; 3Vanderbilt University School of Medicine, Nashville, TN; 4Hackensack University Medical Center, NJ; 5City of Hope National Medical Center, Duarte, CA; 6Rocky Mountain Blood & Marrow Transplant Program, Denver, CO; 7Baylor University School of Medicine, Dallas, TX; 8Oncology & Hematology Associates, Kansas City, MO We tested the hypothesis that oral be- confidence interval [CI] 0.35-1.13) and at tation day 200 was reduced by 91% in the clomethasone dipropionate (BDP) would 30 days follow-up (HR 0.55, 95% CI 0.32- BDP group compared with placebo (HR The survival benefit was .(02. ؍ control gastrointestinal graft-versus-host 0.93). Among patients eligible for pred- 0.09, P disease (GVHD) in patients with anorexia, nisone taper at study day 10, the risk of durable to 1 year after randomization. vomiting, and diarrhea. Patients were ran- GVHD-treatment failure was significantly Oral BDP prevents relapses of gastroin- domized to prednisone for 10 days and reduced at both study days 50 and 80 (HR testinal GVHD following tapering of pred- -or pla- 0.39 and 0.38, respectively).
    [Show full text]